送交者: lijun 于 2006-4-19, 08:44:55:
回答: ZT: 有一篇Nature Medicine的独立文章完全支持魏于全的观点 由 Cheval 于 2006-4-19, 07:02:16:
1. Identification of the relationship between VEGFR-2 and angiogenesis.
2. Discovery of VEGFR-2 as a target for cancer therapy;
3. Monoclonal antibodies and small molecules targeting VEGFR-2 as anti-cancer drugs;
4. Discovery and development of drugs like Nexavar (sorafenib) by Bayer approved by FDA in 12/2005, and Sutent (sunitinib maleate) by Pfizer aprroved by FDA in 1/2006.
5. All drug candidates at clinical trials such as AMG706
by Amgen, Zactima (ZD6474) by AstraZeneca, PKC412 and AEE 788 by Norvatis, AG-013736 by Pfizer, and many others.
After all, Wei is the father of VEGFR-2 and any related scientific discovery and commercial products.